Sesen Bio, Inc. (NASDAQ:SESN) Long Term Investor Alert: Investigation of Potential Wrongdoing
An investigation on behalf of current long term investors in Sesen Bio, Inc. (NASDAQ:SESN) shares over possible breaches of fiduciary duty by certain officers and directors was announced.
San Diego, CA -- (SBWire) -- 11/18/2021 --An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Sesen Bio, Inc.
Investors who are current long term investors in Sesen Bio, Inc. (NASDAQ: SESN) shares, have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm for investors in NASDAQ: SESN stocks follows a lawsuit filed against Sesen Bio, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: SESN stocks, concerns whether certain Sesen Bio directors are liable in connection with the allegations made in that lawsuit.
The plaintiff alleges that, the Defendants failed to disclose to investors, that Sesen Bio's clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as "major", that three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data", that Sesen Bio had submitted the tainted data in connection with the BLA for Vicineum, that Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury, that, as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved, that, as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of Sesen Bio, Inc. (NASDAQ: SESN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Media Relations Contact
View this press release online at: http://rwire.com/1349221